Table 4.
Studies summarizing miscellaneous treatments for BP.
| Author | DRUGS | N° Patients | dose | Primary Endpoint | Safety | Associated Therapies | Phase of Study |
|---|---|---|---|---|---|---|---|
| Pavord ID et al., (2012) [105] Simon D et al. (2020) [106] |
Mepolizumab | 30 | 750 mg four times for four months | Cumulative rate of relapse-free patients after initiation of therapy | No mepolizumab-related adverse events | No | Phase 3 |
| FitzGerald JM et al., (2020) [107] |
Benralizumab | 120 | Subcutaneously (SC) loading dose followed by repeat dosing |
Complete remission at 36 weeks | NA | OCS | Phase 3 |
| Arm JP et al., (2014) [119] |
Ligelizumab | 20 | 240 mg Q2W s.c. | Number of Patients That Had a Clinical Global Assessment of Change (CGA-C) Responder Rate by Week 12 | Phase 2 | ||
|
NCT03099538 (2017) [108] |
Ixekizumab | 4 | SC Ixekizumab 160 at week 0, 80 mg at weeks 2, 4, 6, 8, 10, 12 weeks | Cessation of blister formation | NA | No | Phase 2 |
|
NCT04117932 (2019) [112] |
Ustekinumab | 18 | SC Ustekinumab 90 mg at weeks 0, 4, 16 |
Complete remission | NA | Superpotent TCS | Phase 2 |
|
NCT04465292 (2020) [113] |
Tildrakizumab | 16 | SC Tildrakizumab 100 mg at weeks 0, 4 e 16 |
Change in disease severity | NA | No | Phase 1 |
| Sadik CD et al., (2020) [96] |
Nomacopan | 9 | SC Nomacopan 90 mg at day 1 30 mg daily until day 42 |
Incidence of grade 3, 4 and 5 adverse events | NA | No | Phase 2 |
| Karsten CM et al., (2018) [98] |
Avdoralimab | 40 | 3 SC injections of avdoralimab every week for 12 weeks | Complete clinical remission at 3 months | CLB | Phase 2 underway | |
| Bartko, Johann et al., (2022) [99] |
Sutimlimab | 10 | Test dose of 10 mg/kg, followed by 4 weekly doses of 60 mg/kg EV |
Drug-related Adverse Event for 6 weeks | NA | No | Phase 1 |
| Fiorino, A.S et al., (2019) [101] |
Bertilimumab | 11 | Intravenous 10 mg/kg, 3 doses biweekly | Safety endpoints | PDN 30 mg | Phase 2 | |
| Bilgic-Temel A et al., (2019) [103] |
Dimethyl fumarate |
1 | 120 mg/BD for 7 days and then increased to 240 mg/BD | NA | PDSN 25mg/day DXC 100 mg twice per day (BD), and nicotinamide 500 mg/BD | Case report | |
| Topical therapies | |||||||
|
NCT03286582 (2017) [118] |
AC-203 |
10 | ointment applied twice a day | Incidence of adverse events during the treatment period |
NA | No | Phase 2 |
PDSN = prednisolone; MFM = mycophenolate mofetil; PDN = prednisone; DXC = doxycycline; OCS = oral corticosteroids; TCS = topical corticosteroids CLB = clobetasol propionate.